MedTrace Logo

TNF-α Treatment of Blast-Induced Tinnitus

NCT04066348 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2026-02-23

No results posted yet for this study

Summary

The purpose of this multi-site research study is to determine if Etanercept, compared to a placebo, significantly reduces the severity of tinnitus (ringing in the ears) associated with history of blast and/or noise exposure or associated with Traumatic Brain Injury (TBI) and/or concussion. Individuals who qualify will be randomized into one of two groups: The group receiving the medication Etanercept or the group receiving a saline solution placebo.

Conditions

  • Tinnitus, Noise Induced

Interventions

BIOLOGICAL

Etanercept

To treat blast or noise induced tinnitus

OTHER

Saline

Placebo

Sponsors & Collaborators

  • University of Miami

    collaborator OTHER

  • Michigan Ear Institute

    collaborator UNKNOWN

  • Wayne State University

    lead OTHER

Principal Investigators

  • Jinsheng Zhang, Ph. D. · Wayne State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04066348 on ClinicalTrials.gov